Phase 3 clinical trial shows comparable improvement in quality of life for children with growth hormone deficiency
A 12-month treatment with either once-weekly somatrogon or once-daily somatropin resulted in comparable improvements in health-related quality of life (HRQoL) among children diagnosed with pediatric growth hormone deficiency (pGHD), according to a study.
The study, conducted through a phase 3 clinical trial, utilized the Quality of Life in Short Stature Youth (QoLISSY) questionnaire to assess HRQoL.
The baseline characteristics of the 117 participants were similar across both treatment groups. Among children under 7 years old, QoLISSY-Parent scores in both treatment groups demonstrated improved HRQoL at the 12-month mark compared to baseline. Similarly, self-reported QoLISSY-Child scores in children aged 7 and older indicated HRQoL improvements at 12 months, with somatrogon showing numerically better results than somatropin. Notably, children consistently reported higher HRQoL than perceived by their parents or caregivers at both baseline and 12 months.
This suggests that evaluating HRQoL could be a valuable factor in supporting treatment decisions for children with pGHD undergoing growth hormone therapy.
Reference
Loftus J, Quitmann J, Valluri SR. Health-related quality of life in pre-pubertal children with pediatric growth hormone deficiency: 12-month results from a phase 3 clinical trial of once-weekly somatrogon versus once-daily somatropin. Curr Med Res Opin. 2023;doi: 10.1080/03007995.2023.2290623. Epub ahead of print. PMID: 38053515.
